2004 FEB 2 - (NewsRx.com & NewsRx.net) -- InterMune, Inc., (ITMN) announced the publication in the New England Journal of Medicine of previously presented results of the company's initial randomized, double-blind, placebo-controlled, phase III trial (GIPF-001) evaluating the efficacy and safety of Actimmune (interferon gamma-1b) for the treatment of patients with idiopathic pulmonary fibrosis (IPF), a debilitating and deadly lung disease.
The findings from the GIPF-001 trial form the basis for the company's recently initiated, 600-patient, INSPIRE trial, a randomized, double-blind, placebo-controlled, pivotal, phase III trial. The first patient was enrolled in this …
No comments:
Post a Comment